Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1

Lennox J Jeffers, William Cassidy, Charles D. Howell, Sylvia Hu, K. Rajender Reddy

Research output: Contribution to journalArticle

232 Citations (Scopus)

Abstract

Black Americans (blacks) have a high prevalence of chronic hepatitis C virus (HCV) infection and respond poorly to therapy with interferon alfa-based regimens, but they have been underrepresented in clinical trials. The aim of this study was to assess the rate of sustained virological response (SVR) to peginterferon alfa-2a (40 kd) in combination with ribavirin in black patients chronically infected with HCV genotype 1. In a prospective, multicenter, open-label trial, 78 black and 28 white American interferon-naïve patients were enrolled to receive once weekly subcutaneous injections of 180 μg peginterferon alfa-2a plus oral ribavirin (1000 mg/d for patients weighing less than 75 kg and 1200 mg/d for patients weighing 75 kg or more) for 48 weeks. Pre- and post-treatment liver biopsies were evaluated for necroinflammation and fibrosis. SVR, defined as undetectable (<50 IU/mL) HCV RNA, was 26% in the black group and 39% in the white group. Although the SVR rate was lower in blacks than in whites, the SVR of 26% represents an improvement over previously reported SVR rates from smaller, retrospective studies of black patients. We also observed improvement in fibrosis in 25% of the black patients. No unexpected adverse events occurred. In conclusion, this prospective study evaluating responses of black patients with chronic hepatitis C to peginterferon alfa-2a/ribavirin has demonstrated that treatment can be safely offered to such individuals with reasonable antiviral and histological benefit.

Original languageEnglish
Pages (from-to)1702-1708
Number of pages7
JournalHepatology
Volume39
Issue number6
DOIs
StatePublished - Jun 1 2004

Fingerprint

Ribavirin
Chronic Hepatitis C
Hepacivirus
Genotype
Fibrosis
Virus Diseases
Subcutaneous Injections
Therapeutics
peginterferon alfa-2a
Interferon-alpha
Interferons
Antiviral Agents
Retrospective Studies
Clinical Trials
Prospective Studies
RNA
Biopsy
Liver

ASJC Scopus subject areas

  • Hepatology

Cite this

Jeffers, L. J., Cassidy, W., Howell, C. D., Hu, S., & Reddy, K. R. (2004). Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1. Hepatology, 39(6), 1702-1708. https://doi.org/10.1002/hep.20212

Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1. / Jeffers, Lennox J; Cassidy, William; Howell, Charles D.; Hu, Sylvia; Reddy, K. Rajender.

In: Hepatology, Vol. 39, No. 6, 01.06.2004, p. 1702-1708.

Research output: Contribution to journalArticle

Jeffers, LJ, Cassidy, W, Howell, CD, Hu, S & Reddy, KR 2004, 'Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1', Hepatology, vol. 39, no. 6, pp. 1702-1708. https://doi.org/10.1002/hep.20212
Jeffers, Lennox J ; Cassidy, William ; Howell, Charles D. ; Hu, Sylvia ; Reddy, K. Rajender. / Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1. In: Hepatology. 2004 ; Vol. 39, No. 6. pp. 1702-1708.
@article{548191d5711c4301a542200cefc6c7ce,
title = "Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1",
abstract = "Black Americans (blacks) have a high prevalence of chronic hepatitis C virus (HCV) infection and respond poorly to therapy with interferon alfa-based regimens, but they have been underrepresented in clinical trials. The aim of this study was to assess the rate of sustained virological response (SVR) to peginterferon alfa-2a (40 kd) in combination with ribavirin in black patients chronically infected with HCV genotype 1. In a prospective, multicenter, open-label trial, 78 black and 28 white American interferon-na{\"i}ve patients were enrolled to receive once weekly subcutaneous injections of 180 μg peginterferon alfa-2a plus oral ribavirin (1000 mg/d for patients weighing less than 75 kg and 1200 mg/d for patients weighing 75 kg or more) for 48 weeks. Pre- and post-treatment liver biopsies were evaluated for necroinflammation and fibrosis. SVR, defined as undetectable (<50 IU/mL) HCV RNA, was 26{\%} in the black group and 39{\%} in the white group. Although the SVR rate was lower in blacks than in whites, the SVR of 26{\%} represents an improvement over previously reported SVR rates from smaller, retrospective studies of black patients. We also observed improvement in fibrosis in 25{\%} of the black patients. No unexpected adverse events occurred. In conclusion, this prospective study evaluating responses of black patients with chronic hepatitis C to peginterferon alfa-2a/ribavirin has demonstrated that treatment can be safely offered to such individuals with reasonable antiviral and histological benefit.",
author = "Jeffers, {Lennox J} and William Cassidy and Howell, {Charles D.} and Sylvia Hu and Reddy, {K. Rajender}",
year = "2004",
month = "6",
day = "1",
doi = "10.1002/hep.20212",
language = "English",
volume = "39",
pages = "1702--1708",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1

AU - Jeffers, Lennox J

AU - Cassidy, William

AU - Howell, Charles D.

AU - Hu, Sylvia

AU - Reddy, K. Rajender

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Black Americans (blacks) have a high prevalence of chronic hepatitis C virus (HCV) infection and respond poorly to therapy with interferon alfa-based regimens, but they have been underrepresented in clinical trials. The aim of this study was to assess the rate of sustained virological response (SVR) to peginterferon alfa-2a (40 kd) in combination with ribavirin in black patients chronically infected with HCV genotype 1. In a prospective, multicenter, open-label trial, 78 black and 28 white American interferon-naïve patients were enrolled to receive once weekly subcutaneous injections of 180 μg peginterferon alfa-2a plus oral ribavirin (1000 mg/d for patients weighing less than 75 kg and 1200 mg/d for patients weighing 75 kg or more) for 48 weeks. Pre- and post-treatment liver biopsies were evaluated for necroinflammation and fibrosis. SVR, defined as undetectable (<50 IU/mL) HCV RNA, was 26% in the black group and 39% in the white group. Although the SVR rate was lower in blacks than in whites, the SVR of 26% represents an improvement over previously reported SVR rates from smaller, retrospective studies of black patients. We also observed improvement in fibrosis in 25% of the black patients. No unexpected adverse events occurred. In conclusion, this prospective study evaluating responses of black patients with chronic hepatitis C to peginterferon alfa-2a/ribavirin has demonstrated that treatment can be safely offered to such individuals with reasonable antiviral and histological benefit.

AB - Black Americans (blacks) have a high prevalence of chronic hepatitis C virus (HCV) infection and respond poorly to therapy with interferon alfa-based regimens, but they have been underrepresented in clinical trials. The aim of this study was to assess the rate of sustained virological response (SVR) to peginterferon alfa-2a (40 kd) in combination with ribavirin in black patients chronically infected with HCV genotype 1. In a prospective, multicenter, open-label trial, 78 black and 28 white American interferon-naïve patients were enrolled to receive once weekly subcutaneous injections of 180 μg peginterferon alfa-2a plus oral ribavirin (1000 mg/d for patients weighing less than 75 kg and 1200 mg/d for patients weighing 75 kg or more) for 48 weeks. Pre- and post-treatment liver biopsies were evaluated for necroinflammation and fibrosis. SVR, defined as undetectable (<50 IU/mL) HCV RNA, was 26% in the black group and 39% in the white group. Although the SVR rate was lower in blacks than in whites, the SVR of 26% represents an improvement over previously reported SVR rates from smaller, retrospective studies of black patients. We also observed improvement in fibrosis in 25% of the black patients. No unexpected adverse events occurred. In conclusion, this prospective study evaluating responses of black patients with chronic hepatitis C to peginterferon alfa-2a/ribavirin has demonstrated that treatment can be safely offered to such individuals with reasonable antiviral and histological benefit.

UR - http://www.scopus.com/inward/record.url?scp=2542590982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542590982&partnerID=8YFLogxK

U2 - 10.1002/hep.20212

DO - 10.1002/hep.20212

M3 - Article

C2 - 15185312

AN - SCOPUS:2542590982

VL - 39

SP - 1702

EP - 1708

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -